A股異動 | 華潤三九漲5% 與賽諾菲消費者健康藥業就"易善復"續簽十年合約
格隆匯11月8日丨華潤三九(000999.SZ)漲5.04%,報53.15元,總市值525億元。消息面上,賽諾菲消費者健康藥業於第五屆中國國際進口博覽會期間,與華潤三九簽署戰略合作協議。賽諾菲消費者健康藥業與華潤三九的合作始於2016年,雙方重點合作產品"易善復"佔據口服肝臟類目中的領先份額。基於多年來良好的合作與信任基礎,雙方就合作產品"易善復"續簽了為期十年的戰略合作協議。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.